Scientific Reports · 2019 · 60 citations · 27 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyAutophagy In CancerBladder CancerCancer ImmunotherapyCytotoxic ChemotherapyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityAnticancer ChemotherapyCancer Cell Proliferation InhibitionCell Cycle Arrest MechanismsCell Cycle Arrest SignalingImmune Effector MoleculesKinase InhibitorsTherapeutic Target Identification
Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3β inhibitor, 9-ING-41, currently in clinical studies in patients with advanced cancer, in bladder cancer cell lines. We found that treatment with 9-ING-41 leads to cell cycle arrest, autophagy and apoptosis in bladder cancer cells. The autophagy inhibitor chloroquine potentiated the antitumor effects of 9-ING-41 when tested in combination studies. Our findings also demonstrate that 9-ING-41 enhanced the growth inhibitory effects of gemcitabine or cisplatin when used in combination in bladder cancer cells. Finally, we found that 9-ING-41 sensitized bladder cancer cells to the cytotoxic effects of human immune effector cells. Our results provide a rationale for the inclusion of patients with advanced bladder cancer in clinical studies of 9-ING-41.
27
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Klaus P. Hoeflich, Juan Luo, Elizabeth A. Rubie et al. · Nature · 2000 · 1.4K citations